10 Stocks To Trade Without Tariffs And Interest Rate Fears

3. Moderna, Inc. (NASDAQ:MRNA) 

Moderna, Inc. operates as a biotechnology company that develops, discovers, and markets messenger RNA therapeutics and vaccines. The company provides treatment of immuno-oncology, autoimmune, cardiovascular diseases, rare diseases, and infectious diseases.

MRNA recently extended its partnership with Merck to develop mRNA-based Personalized Cancer Vaccines (PCVs). This vaccine will be used with KEYTRUDA (pembrolizumab), which is the best-selling cancer treatment drug across the world. This collaboration has great potential to boost the company’s growth:

“There are positive signs going into 2025. The market volume for COVID-19 vaccines has been relatively stable for two years, and public health recommendations for vaccinations are normalizing. We are encouraged to see the emergence of a sizable and durable long-term COVID-19 vaccine market.”

The firm revised its guidance for 2025 from $2.5 billion to $1.5 billion which is disappointing. The main reason behind this is struggles in the RSV market and reducing demand for COVID-19 vaccines. MRNA’s stock was at its peak during COVID-19 as it went from $11.54 to $497, but after the pandemic, the stock fell sharply and continues to do so.

Now the company is focused on developing new vaccines including a seasonal flu vaccine (mRNA-1010), a vaccine for COVID-19, and influenza, and vaccines for cytomegalovirus (CMV) and norovirus. It has 9 vaccines in the final phase and the management is also expecting approval of 3 new products in 2025.

With collaboration and product innovation, the company is set to grow steadily. The stock has lost 70% of its value in a year and the lowered guidance is priced in. Once investors realize the strong pipeline of products, the stock could reverse for a bull rally.